May 22, 2018

Ranbaxy Recalling Atorvastatin Calcium Tablets for Possible Contamination

Ranbaxy Inc. is recalling Atorvastatin Calcium Supplements because they may contain very small glass particles that are tinier than a grain of sand. There have not been any reports of adverse events related to the recall.

The products are in 10 mg, 20 mg, and 40 mg solid oral dosage form. This recall does not affect the 80 mg dosage strength. The size of the glass particles is to small that a significant safety concern is unlikely, but still possible. The product is used to lower blood cholesterol. It’s packaged in plastic bottles as 90 and 500 tablets per bottle. You can see theĀ long list of lot numbers, NDC numbers, and expiration dates at the FDA site.

If anyone has an adverse reaction to this product, see a health care provider immediately, thenĀ report it at the FDA’s MedWatch Adverse Event Reporting Program. Ranbaxy Inc. is a wholly owned subsidiary of Ranbaxy Laboratories Limited, India’s largest pharmaceutical company. If you have questions about this recall, call Ranbaxy’s Customer Coordinator at 1-866-266-7623 Monday through Friday from 8:00 am to 5:00 pm CT.

Report Your Food Poisoning Case
[contact-form-7 404 "Not Found"]

Home About Site Map Contact Us Sponsored by Pritzker Hageman, P.A., a Minneapolis, MN law firm that helps food poisoning victims nationally.